维拉帕米对新诊断儿童1型糖尿病胰腺β细胞功能的影响:一项随机临床试验
这项双盲随机临床试验在美国6个中心纳入88例7至17岁、新诊断1型糖尿病且体重≥30 kg的儿童和青少年,按1:1随机分配至每日一次口服维拉帕米(47例)或安慰剂(41例)。52周时,维拉帕米组混合餐耐量试验刺激的C肽曲线下面积较安慰剂组高0.14 pmol/mL(95%CI 0.01至0.27 pmol/mL;P=0.04),相当于C肽水平高30%。作者结论认为维拉帕米部分保留了刺激后C肽分泌,需进一步研究确定其纵向持久性和最佳治疗时长。
要点
- 在新诊断儿童1型糖尿病中,维拉帕米52周时使刺激后C肽曲线下面积较安慰剂高0.14 pmol/mL(95%CI 0.01至0.27;P=0.04)。
- 维拉帕米组52周C肽峰值≥0.2 pmol/mL者占95%(41/43),安慰剂组占71%(27/38)。
- 52周糖化血红蛋白维拉帕米组6.6% vs 安慰剂组6.9%(校正组间差-0.3%,95%CI -1.0%至0.4%)。
核心结论
- 在新诊断1型糖尿病的儿童和青少年中,与安慰剂相比,维拉帕米在诊断后52周部分保留了刺激后C肽分泌。
研究设计与样本
- 双盲随机临床试验,在美国6个中心纳入7至17岁、新诊断1型糖尿病且体重≥30 kg的儿童和青少年,2020年7月20日至2021年10月13日随机分组,随访于2022年9月15日完成。
- 采用析因设计,参与者按1:1随机分配至每日一次口服维拉帕米(n=47)或安慰剂(n=41),同时被分配接受强化糖尿病管理或标准糖尿病照护。
- 共88例参与者,平均年龄12.7岁(SD 2.4),女性36例(41%),从诊断到随机分组的平均时间24天(SD 4),83例(94%)完成试验。
主要发现
- 维拉帕米组C肽曲线下面积基线为0.66 pmol/mL、52周为0.65 pmol/mL,安慰剂组基线为0.60 pmol/mL、52周为0.44 pmol/mL(校正组间差0.14 pmol/mL,95%CI 0.01至0.27 pmol/mL;P=0.04),相当于维拉帕米组52周C肽水平高30%。
- 52周C肽峰值≥0.2 pmol/mL的参与者比例维拉帕米组为95%(41/43),安慰剂组为71%(27/38)。
- 52周糖化血红蛋白维拉帕米组为6.6%,安慰剂组为6.9%(校正组间差-0.3%,95%CI -1.0%至0.4%)。
- 维拉帕米组8例(17%)和安慰剂组8例(20%)发生被认为与治疗相关的不严重不良事件。
局限性
- 作者结论指出,需要进一步研究以确定C肽改善的纵向持久性和最佳治疗时长。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In preclinical studies, thioredoxin-interacting protein overexpression induces pancreatic beta cell apoptosis and is involved in glucotoxicity-induced beta cell death. Calcium channel blockers reduce these effects and may be beneficial to beta cell preservation in type 1 diabetes. OBJECTIVE: To determine the effect of verapamil on pancreatic beta cell function in children and adolescents with newly diagnosed type 1 diabetes. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, randomized clinical trial including children and adolescents aged 7 to 17 years with newly diagnosed type 1 diabetes who weighed 30 kg or greater was conducted at 6 centers in the US (randomized participants between July 20, 2020, and October 13, 2021) and follow-up was completed on September 15, 2022. INTERVENTIONS: Participants were randomly assigned 1:1 to once-daily oral verapamil (n = 47) or placebo (n = 41) as part of a factorial design in which participants also were assigned to receive either intensive diabetes management or standard diabetes care. MAIN OUTCOMES AND MEASURES: The primary outcome was area under the curve values for C-peptide level (a measure of pancreatic beta cell function) stimulated by a mixed-meal tolerance test at 52 weeks from diagnosis of type 1 diabetes. RESULTS: Among 88 participants (mean age, 12.7 [SD, 2.4] years; 36 were female [41%]; and the mean time from diagnosis to randomization was 24 [SD, 4] days), 83 (94%) completed the trial. In the verapamil group, the mean C-peptide area under the curve was 0.66 pmol/mL at baseline and 0.65 pmol/mL at 52 weeks compared with 0.60 pmol/mL at baseline and 0.44 pmol/mL at 52 weeks in the placebo group (adjusted between-group difference, 0.14 pmol/mL [95% CI, 0.01 to 0.27 pmol/mL]; P = .04). This equates to a 30% higher C-peptide level at 52 weeks with verapamil. The percentage of participants with a 52-week peak C-peptide level of 0.2 pmol/mL or greater was 95% (41 of 43 participants) in the verapamil group vs 71% (27 of 38 participants) in the placebo group. At 52 weeks, hemoglobin A1c was 6.6% in the verapamil group vs 6.9% in the placebo group (adjusted between-group difference, -0.3% [95% CI, -1.0% to 0.4%]). Eight participants (17%) in the verapamil group and 8 participants (20%) in the placebo group had a nonserious adverse event considered to be related to treatment. CONCLUSIONS AND RELEVANCE: In children and adolescents with newly diagnosed type 1 diabetes, verapamil partially preserved stimulated C-peptide secretion at 52 weeks from diagnosis compared with placebo. Further studies are needed to determine the longitudinal durability of C-peptide improvement and the optimal length of therapy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04233034.
引用
- Forlenza GP, McVean J, Beck RW, et al. Effect of Verapamil on Pancreatic Beta Cell Function in Newly Diagnosed Pediatric Type 1 Diabetes: A Randomized Clinical Trial. JAMA. 2023. PMID: 36826844. doi:10.1001/jama.2023.2064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。